Description: The BTLA monoclonal antibody reacts with human B and T lymphocyte attenuator (BTLA). BTLA is expressed by peripheral lymphocytes, splenic macrophages, developing B cells in the bone marrow and developing T cells in the thymus and mature, but not immature bone marrow-derived dendritic cells. BTLA is implicated as a negative regulator of the activation and/or function of various hemopoietic cell types. It is reported that BTLA binds to B7-H4, but further studies are needed to confirm this interaction.
Applications Reported: This MIH26 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This MIH26 antibody has been tested by flow cytometric analysis of nomral human peripheral blood. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 . and CTLA4 ., BTLA interacts with a B7 homolog, B7H4.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.